Prospective evaluation of the combined value of physical examination and biomarker variables in screening for preclinical dilated cardiomyopathy in Doberman Pinschers

Gordon, Sonya G.; Wesselowski, Sonya; Estrada, Amara H.; Braz-Ruivo, L; Morris, Nicholas; Häggström, Jens; O'Grady, Michael R.; Malcolm, Elizabeth

doi:10.1016/j.jvc.2022.01.004

Cited by 3 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Серцевий тропонін I є білком, характерним для кардіоміоцитів, який бере участь у скороченні та розслабленні серця. Цей протеїн прикріплений до нитки актину і в помірній кількості присутній у цитоплазмі, тому під час пошкодження кардіоміоцитів позаклітинний cTnI вивільняється, надходить в кров і є специфічним біомаркером ураження клітин серця (Oyama, 2015;Gordon et al, 2022). Водночас у крові клінічно здорових тварин вміст cTnI незначний або частіше відсутній (Oyama, 2013).…”

Section: вступunclassified

Biochemical changes in the blood of domestic dogs with cardiomyopathy in the setting of obesity

Zarytskyi

2024

SMLNUVMB

View full text Add to dashboard Cite

In clinical settings, cardiac biomarkers with high sensitivity and specificity can be used to predict or diagnose heart disease. In humane clinical practice, troponins I and T have been used as predictors of heart disease, and the concentration of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is also considered the most reliable predictor of heart disease. Veterinary cardiac biomarkers are not yet widely used by practitioners in the diagnosis of heart disease, but this does not negate the high informative value of specific cardiac parameters such as canine N-terminal pro-B-type natriuretic peptide (cNT-proBNP) and canine cardiac troponin I (ccTnI). Given the above, there is a need to conduct biochemical blood tests for cardiac pathology in dogs. The aim of the study was to determine specific parameters (cNT-proBNP and ccTnI) and blood lipidogram of domestic dogs with cardiomyopathy in the setting of obesity. The analysis of blood tests showed an increase in the content of ccTnI by more than 20 times (Р < 0.001) and cNT-pro BNP by 17.6 times (Р < 0.001) in domestic dogs with cardiomyopathy in the setting of obesity. According to the results of lipidogram determination, the dogs of the experimental group showed an increase in total cholesterol by 66.9 %, low-density lipoprotein (LDL) by 8.4 times, and very low-density lipoprotein (VLDL) by 4.2 times. The studies showed significant changes in blood biochemical parameters in cardiomyopathy in domestic dogs with obesity, which confirms the diagnostic value of these biomarkers. The research results deserve the attention of the veterinary community of practitioners and can be used in the diagnosis and subsequent prognosis of heart disease in the future.

show abstract

Section: вступunclassified

Biochemical changes in the blood of domestic dogs with cardiomyopathy in the setting of obesity

Zarytskyi

2024

SMLNUVMB

View full text Add to dashboard Cite

show abstract

“…High‐sensitivity cTnI assays have also demonstrated good ability to differentiating Doberman pinschers with preclinical echocardiographic DCM phenotypes from healthy Doberman pinschers and those that have other cardiac diseases, for instance MMVD (Gordon and others 2022). In terms of cTnI's ability to be used as a prognostic indicator, there is a lack of consensus around the exact utility; however, high values (>0.7 ng/mL) are an independent predictor of poor prognosis in cats with HCM (Borgeat and others 2014).…”

Section: Cardiac Troponin‐i Assaysmentioning

confidence: 99%

“…When the cut‐off value increases to at least 827 pmol/l, the sensitivity was 77.3 per cent with an improved specificity at 90.1 per cent. When combined with a complete physical examination (eg, looking for the presence of any heart murmur and/or arrhythmias) and three‐minute ECG, the biomarker results could determine whether the patient would benefit from advanced diagnostics (Gordon and others 2022). As such, this combination may be useful when there are financial limitations present.…”

Section: B‐type Natriuretic Peptide and N‐terminal Pro B‐type Natriur...mentioning

confidence: 99%

Interpreting cardiac biomarkers in small animal practice

Bode,

Lau

2023

In Practice

View full text Add to dashboard Cite

Background: Cardiac troponin‐I (cTnI) and N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) are two cardiac biomarkers readily available on the market. These two biomarkers are useful diagnostic tools used in the right setting: differentiating cardiac and non‐cardiac causes of respiratory distress and providing prognosis prediction. However, these tests have their limitations and their results should be interpreted with these limitations in mind.Aim of the article: This article reviews the available evidence around the physiology of cTnI and NT‐proBNP – the commercially available assays – and discusses their indications, limitations and result interpretation for each biomarker. The emerging biomarker, microRNA, is also briefly discussed.

show abstract

“…The ADVIA Centaur TnI-Ultra assay, henceforth referred to as AC-cTnI-U, is an ultrasensitive cTnI assay validated for use in the dog (6, 7) that has a detection limit of 0.006-50.0 ng/ mL. The AC-cTnI-U assay has been widely used for clinical veterinary patients and in clinical veterinary research [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23], however, this assay has now been retired and replaced by the ADVIA Centaur XP High-Sensitivity Troponin I assay, henceforth referred to as AC-cTnI-HS. For a troponin assay to be considered high sensitivity, cTnI must be detectable above the limit of detection and below the 99 th percentile upper reference limit of normal in at least half of the population, with a coefficient of variation (CV) <10%, as described in a recent review on evaluating analytical performance of troponin immunoassays [24].…”

Section: Introductionmentioning

confidence: 99%

Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay

et al. 2023

View full text Add to dashboard Cite

Cardiac troponin I (cTnI) is considered the gold standard biomarker for myocardial injury and shows a high degree of homology between humans and dogs. The ADVIA Centaur XP High-Sensitivity Troponin I (AC-cTnI-HS) assay has been validated for use in humans but not dogs. The study objectives were to analytically validate the AC-cTnI-HS assay in dogs, to assess correlation between the AC-cTnI-HS and a previous ADVIA Centaur TnI-Ultra (AC-cTnI-U) assay, to assess cTnI sample storage stability, and to clinically evaluate the AC-cTnI-HS assay in healthy dogs and dogs with cardiac disease. Canine serum samples were used for analytical validation. Intra- and inter-assay variability, dilutional parallelism, and spiking recovery were assessed. Samples from 196 client-owned dogs were evaluated (healthy dogs (n = 39) or dogs with congenital heart disease (n = 54), myxomatous mitral valve disease (n = 68), dilated cardiomyopathy (n = 15), or myocarditis (n = 20)). Inter- and intra-assay coefficient of variation (%CV) was between 2.8–41.4% and 3.8–30.2%, respectively, with pools with concentrations >20 pg/mL all having %CVs <10%. The observed to expected ratios for dilutional parallelism and spiking recovery experiments ranged between 92.3 and 266.7.0% and 84.3 and 108%, respectively. A strong correlation between the AC-cTnI-HS and AC-cTnI-U assays was observed (Spearman’s ρ = 0.927), though a proportional bias existed, with AC-cTnI-HS assay concentrations being proportionally lower than AC-cTnI-U assay concentrations. Serum samples stored at -80°C had stable cTnI measurements for up to 2.7 years and after a single freeze-thaw cycle. Healthy dogs and dogs with congenital heart disease had significantly lower cTnI concentrations than dogs in the other three groups. The AC-cTnI-HS assay precisely, reproducibly, and accurately measures cTnI concentrations in dog serum with cTnI concentrations >20 pg/mL.

show abstract

Prospective evaluation of the combined value of physical examination and biomarker variables in screening for preclinical dilated cardiomyopathy in Doberman Pinschers

Cited by 3 publications

References 19 publications

Biochemical changes in the blood of domestic dogs with cardiomyopathy in the setting of obesity

Biochemical changes in the blood of domestic dogs with cardiomyopathy in the setting of obesity

Interpreting cardiac biomarkers in small animal practice

Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay

Contact Info

Product

Resources

About